Current and emerging treatment strategies for breast cancer-induced bone loss

References

• American Cancer SocietyCancer Facts and Figures 2010Atlanta, GAAmerican Cancer Society2010
   Google Scholar
• BruningPFPitMJde Jong-BakkerMvan den EndeAHartAvan EnkABone mineral density after adjuvant chemotherapy for premenopausal breast cancerBr J Cancer19906123083102310683
   PubMed Web of Science ®Google Scholar
• ShapiroCLManolaJLeboffMOvarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancerJ Clin Oncol200119143306331111454877
   PubMed Web of Science ®Google Scholar
• HeadleyJATheriaultRLLeBlandADVassilopoulou-SellinRHortobagyiGNPilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapyCancer Investig19981616119474245
   PubMed Web of Science ®Google Scholar
• PartridgeAHBursteinHJWinerEPSide effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancerJ Natl Cancer Inst Monogr20013013514211773307
   PubMedGoogle Scholar
• GoodwinPJEnnisMPritchardKITrudeauMHoodNRisk of menopause during the first year after breast cancer diagnosisJ Clin Oncol19991782365237010561298
   PubMed Web of Science ®Google Scholar
• BinesJOleskeDMCobleighMAOvarian function in premenopausal women treated with adjuvant chemotherapy for breast cancerJ Clin Oncol1996145171817298622093
   PubMed Web of Science ®Google Scholar
• PowlesTJHickishTKanisJATidyAAshleySEffect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal womenJ Clin Oncol199614178848558225
   PubMed Web of Science ®Google Scholar
• JakeszRJonatWGnantMSwitching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trialLancet200536645546216084253
   PubMed Web of Science ®Google Scholar
• CoombesRCHallEGibsonLJA randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women primary breast cancerN Engl J Med2004350111081109215014181
   PubMed Web of Science ®Google Scholar
• CoatesASKeshaviahAThürlimannBFive years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98J Clin Oncol200725548649217200148
   PubMed Web of Science ®Google Scholar
• ThürlimannBKeshaviahACoatesASfor Breast International Group (BIG) 1–98 Collaborative GroupA comparison of letrozole and tamoxifen in postmenopausal women with early breast cancerN Engl J Med2005353262747275716382061
   PubMed Web of Science ®Google Scholar
• GossPEIngleJNMartinoSA randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancerN Engl J Med2003349191793180214551341
   PubMed Web of Science ®Google Scholar
• BaumMBudzarAUCuzickJfor The Arimidex, Tamoxifen, Alone or in Combination Trialists’ GroupAnastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trialLancet20023592131213912090977
   PubMed Web of Science ®Google Scholar
• BaumMBudzarAUCuzickJfor The Arimidex, Tamoxifen, Alone or in Combination Trialists’ GroupAnastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: results of the ATAC trial efficacy and safety update analysesCancer20039891802181014584060
   PubMed Web of Science ®Google Scholar
• ForbesJFCuzickJBuzdarAHowellATobiasJSBaumMfor The Arimidex, Tamoxifen, Alone or in Combination Trialists’ GroupEffect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialLancet Oncol20089455318083636
   PubMed Web of Science ®Google Scholar
• ColemanREBanksLMGirgisSISkeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomized controlled studyLancet Oncol2007811912717267326
   PubMed Web of Science ®Google Scholar
• PerezEAJosseRGPritchardKIEffect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17J Clin Oncol200624223629363516822845
   PubMed Web of Science ®Google Scholar
• EastellRHannonRACuzickJDowsettMClackGAdamsJEEffect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trialJ Bone Miner Res2006211215122316869719
   PubMed Web of Science ®Google Scholar
• ColemanREfor ATAC Trialists’ GroupEffect of anastrozole on bone mineral density: 5-year results from the “Arimidex“ Tamoxifen, Alone or in combination (ATAC) trialJ Clin Oncol20062418S511
   Google Scholar
• KanisJAMcCloskeyEVPowlesTPatersonAHGAshleySSpectorTA high incidence of vertebral fracture in women with breast cancerBr J Cancer1999797/81179118110098755
   PubMed Web of Science ®Google Scholar
• BrufskyAHarkerWGBeckJTZoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancerJ Clin Oncol200725782983617159193
   PubMed Web of Science ®Google Scholar
• HinesSLMinceyBDentchevTImmediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CCBreast Cancer Res Treat200911760360919214743
   PubMed Web of Science ®Google Scholar
• LesterJEDodwellDPurohitOPPrevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancerClin Cancer Res200814196336634218829518
   PubMed Web of Science ®Google Scholar
• van PoznakCHannonRAMackeyJRPrevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trialJ Clin Oncol201028696797520065185
   PubMed Web of Science ®Google Scholar
• GreenspanSLBhattacharyaRKSereikaSMBrufskyAVogelVGPrevetnion of bone loss in survivors of breast cancer: a randomized double-blind, placebo-controlled clinical trialJ Clin Endocrinol Metab20079213113617047022
   PubMed Web of Science ®Google Scholar
• DelmasPDBalenaRConfravreuxEHardouinCHardyPBremondABisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled studyJ Clin Oncol19971539559629060533
   PubMed Web of Science ®Google Scholar
• HinesSLSloanJAAthertonPJZoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapyBreast201019929620079640
   PubMed Web of Science ®Google Scholar
• HinesSLMinceyBASloanJAPhase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancerJ Clin Oncol20092771047105319075260
   PubMed Web of Science ®Google Scholar
• SaartoTBlomqvistCVälimäkiMPäkeläPSarnaSElomaaIChemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patientsJ Clin Oncol1997154134113479193325
   PubMed Web of Science ®Google Scholar
• PowlesTJMcCloskeyEPatersonAHGOral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancerJ Natl Cancer Inst1998907047089586668
   PubMed Web of Science ®Google Scholar
• GnantMFXMlineritschBLuschin-EbengreuthGZoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endrocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study GroupJ Clin Oncol200725782082817159195
   PubMed Web of Science ®Google Scholar
• Fouque-AubertAChapurlatRInfluence of RANKL inhibition on immune system in the treatment of bone diseasesJoint Bone Spine20087551017920324
   PubMed Web of Science ®Google Scholar
• McClungMRLewieckiEMCohenSTDenosumab in postmenopausal women with low bone mineral densityN Engl J Med2006354882183116495394
   PubMed Web of Science ®Google Scholar
• LiptonAStegerGGFigueroaJRandomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastasesJ Clin Oncol200725284431443717785705
   PubMed Web of Science ®Google Scholar
• BodyJJFaconTColemanREA study of the biological receptor activator of nuclear factor-kB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancerClin Cancer Res20061241221122816489077
   PubMed Web of Science ®Google Scholar
• FizaziKLiptonAMarietteXRandomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonatesJ Clin Oncol200927101564157119237632
   PubMed Web of Science ®Google Scholar
• EllisGKBoneHGChlebowskiRRandomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancerJ Clin Oncol200826304875488218725648
   PubMed Web of Science ®Google Scholar
• WattsNBCooperCLindsayRRelationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture riskJ Clin Densitom20047325526115319494
   PubMed Web of Science ®Google Scholar